LLY

971.94

-1.55%↓

JNJ

220.82

-1.05%↓

ABBV

202.3

-0.97%↓

UNH

367.04

-0.29%↓

AZN

181.19

-1.38%↓

LLY

971.94

-1.55%↓

JNJ

220.82

-1.05%↓

ABBV

202.3

-0.97%↓

UNH

367.04

-0.29%↓

AZN

181.19

-1.38%↓

LLY

971.94

-1.55%↓

JNJ

220.82

-1.05%↓

ABBV

202.3

-0.97%↓

UNH

367.04

-0.29%↓

AZN

181.19

-1.38%↓

LLY

971.94

-1.55%↓

JNJ

220.82

-1.05%↓

ABBV

202.3

-0.97%↓

UNH

367.04

-0.29%↓

AZN

181.19

-1.38%↓

LLY

971.94

-1.55%↓

JNJ

220.82

-1.05%↓

ABBV

202.3

-0.97%↓

UNH

367.04

-0.29%↓

AZN

181.19

-1.38%↓

Inicio・Lista de Acciones・Compugen Ltd

Compugen Ltd

Abierto

2.88 4.35

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.71

Máximo

2.92

Métricas clave
By Trading Economics
Ingresos	64M 57M
Ventas	65M 67M
P/B Media del Sector	7.135 49.8
Margen de beneficios	84.425
Empleados	75
EBITDA	63M 56M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+76.89% upside

Dividendos
By Dow Jones
Próximas Ganancias	18 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	38M 250M
Apertura anterior	-1.47
Cierre anterior	2.88

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.25 / 1.48 Soporte y Resistencia

Compugen Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

6 may 2026, 23:41 UTC

Ganancias

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 may 2026, 21:40 UTC

Ganancias

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 may 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 may 2026, 23:34 UTC

Charlas de Mercado

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 may 2026, 23:13 UTC

Ganancias

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 may 2026, 23:13 UTC

Ganancias

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 may 2026, 23:12 UTC

Ganancias

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 may 2026, 23:11 UTC

Ganancias

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 may 2026, 23:11 UTC

Ganancias

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 may 2026, 23:11 UTC

Ganancias

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 may 2026, 23:11 UTC

Ganancias

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 may 2026, 23:11 UTC

Ganancias

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 may 2026, 23:11 UTC

Ganancias

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 may 2026, 23:07 UTC

Ganancias

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 may 2026, 23:06 UTC

Ganancias

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 may 2026, 23:06 UTC

Ganancias

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 may 2026, 23:05 UTC

Ganancias

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 may 2026, 23:04 UTC

Ganancias

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 may 2026, 22:50 UTC

Ganancias

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 may 2026, 22:25 UTC

Charlas de Mercado

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 may 2026, 22:11 UTC

Ganancias

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 may 2026, 22:11 UTC

Ganancias

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 may 2026, 22:05 UTC

Charlas de Mercado

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 may 2026, 21:58 UTC

Ganancias

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 may 2026, 21:47 UTC

Charlas de Mercado

Ganancias

Costco Posts 13% Sales Growth in April -- Market Talk

6 may 2026, 21:46 UTC

Ganancias

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 may 2026, 21:40 UTC

Ganancias

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 may 2026, 21:35 UTC

Charlas de Mercado

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 may 2026, 21:32 UTC

Acciones populares

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 may 2026, 21:29 UTC

Ganancias

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Comparación entre iguales

Cambio de precio

Compugen Ltd previsión

Precio Objetivo

By TipRanks

76.89% repunte

Estimación a 12 Meses

Media 4.67 USD 76.89%

Máximo 6 USD

Mínimo 4 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Compugen Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

Comprar

Mantener

Vender

De acuerdo con 3 analistas que ofrecen calificaciones bursátiles a para Compugen Ltd Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.25 / 1.48Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.